Reduced brain glutamate in patients with Parkinson's disease

NMR in Biomedicine

Volumn 21, Issue 4, 2008, Pages 381-387

  Griffith, H Randall ^a,b,c,d   Okonkwo, Ozioma C ^c   O'Brien, Timothy ^c   den Hollander, Jan A ^c  

^a The University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d ABPP CN   (United States)

Author keywords

Brain metabolism; Glutamate; Parkinson's disease; Spectroscopy

Indexed keywords

DISEASES; MAGNETIC RESONANCE SPECTROMETERS; METABOLISM; ORGANIC COMPOUNDS;

CEREBRAL CORTEX; GLUTAMATE; PARKINSON'S DISEASE;

BRAIN;

AMANTADINE; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; CHOLINE; CREATINE; CREATINE PHOSPHATE; ENTACAPONE; GLUTAMIC ACID; N ACETYLASPARTIC ACID; PRAMIPEXOLE; ROPINIROLE;

ADULT; AGED; ARTICLE; BRAIN CORTEX; BRAIN LEVEL; BRAIN METABOLISM; CINGULATE GYRUS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; HUMAN; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE;

AGED; BRAIN; DEMOGRAPHY; FEMALE; GLUTAMIC ACID; GYRUS CINGULI; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; PARKINSON DISEASE;

ANIMALIA;

EID: 44649159592     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.1203     Document Type: Article

References (41)

1. Feinberg TE, Farah MJ. Behavioral Neurology and Neuropsychology. McGraw-Hill: New York, 1997.
2. Hagell P, Nordling S, Reimer J, Grabowski M, Persson U. Resource use and costs in a Swedish cohort of patients with Parkinson's disease. Mov. Disord. 2002; 17: 1213-1220.
3. Whetten-Goldstein K, Sloan F, Kulas E, Cutson T, Schenkman M. The burden of Parkinson's disease on society, family, and the individual. J. Am Geriatr. Soc. 1997; 45: 844-849.
4. Mueller SG, Schuff N, Weiner MW. Evaluation of treatment effects in Alzheimer's and other neurodegenerative diseases by MRI and MRS. NMR Biomed. 2006; 19: 655-668.
5. 1H magnetic resonance spectroscopy and MRI of Parkinson's disease. Mov. Disord. 2002; 17: 917-927.
6. Federico F, Simone IL, Lucivero V, De Mari M, Giannini P, Iliceto G, Mezzapesa DM, Lamberti P. Proton magnetic resonance spectroscopy in Parkinson's disease and progressive supra-nuclear palsy. J. Neurol. Neurosurg. Psychiatry 1997; 62: 239-242.
7. Ellis CM, Lemmens G, Williams SC, Simmons A, Dawson J, Leigh PN, Chaudhuri KR. Changes in putamen N-acetylaspartate and choline ratios in untreated and levodopa-treated Parkinson's disease: a proton magnetic resonance spectroscopy study. Neurology 1997; 49: 438-444.
8. Taylor-Robinson SD, Turjanski N, Bhattacharya S, Seery JP, Sargentoni J, Brooks DJ, Bryant DJ, Cox IJ. A proton magnetic resonance spectroscopy study of the striatum and cerebral cortex in Parkinson's disease. Metab Brain Dis. 1999; 14: 45-55.
9. 1H-MRS) of motor cortex and basal ganglia in de novo Parkinson's disease patients. Neurol. Sci. 2001; 22: 69-70.
10. Hu MT, Taylor-Robinson SD, Chaudhuri KR, Bell JD, Morris RG, Clough C, Brooks DJ, Turjanski N. Evidence for cortical dysfunction in clinically non-demented patients with Parkinson's disease: a proton MR spectroscopy study. J. Neurol. Neurosurg. Psychiatry 1999; 67: 20-26.
11. Camicioli RM, Korzan JR, Foster SL, Fisher NJ, Emery DJ, Bastos AC, Hanstock CC. Posterior cingulate metabolic changes occur in Parkinson's disease patients without dementia. Neurosci. Lett. 2004; 354: 177-180.
12. Bowen BC, Block RE, Sanchez-Ramos J, Pattany PM, Lampman DA, Murdoch JB, Quencer RM. Proton MR spectroscopy of the brain in 14 patients with Parkinson disease. AJNR Am J. Neuroradiol. 1995; 16: 61-68.
13. Tedeschi G, Litvan I, Bonavita S, Bertolino A, Lundbom N, Patronas NJ, Hallett M. Proton magnetic resonance spectroscopic imaging in progressive supranuclear palsy, Parkinson's disease and corticobasal degeneration. Brain 1997; 120 (Pt 9): 1541-1552.
14. Clarke CE, Lowry M, Horsman A. Unchanged basal ganglia N-acetylaspartate and glutamate in idiopathic Parkinson's disease measured by proton magnetic resonance spectroscopy. Mov. Disord. 1997; 12: 297-301.
15. Robelet S, Melon C, Guillet B, Salin P, Kerkerian-Le Goff L. Chronic L-DOPA treatment increases extracellular glutamate levels and GLT1 expression in the basal ganglia in a rat model of Parkinson's disease. Eur. J. Neurosci. 2004; 20: 1255-1266.
16. Greenamyre JT, Ellen RV, Zhang Z, Ovadia A, Kurlan R, Gash DM. Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease. Ann. Neurol. 1994; 35: 655-661.
17. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci. 1989; 12: 366-375.
18. Phillips JM, Lam HA, Ackerson LC, Maidment NT. Blockade of mGluR glutamate receptors in the subthalamic nucleus ameliorates motor asymmetry in an animal model of Parkinson's disease. Eur. J. Neurosci. 2006; 23: 151-160.
19. Murray TK, Whalley K, Robinson CS, Ward MA, Hicks CA, Lodge D, Vandergriff JL, Baumbarger P, Siuda E, Gates M, Ogden AM, Skolnick P, Zimmerman DM, Nisenbaum ES, Bleakman D, O'Neill MJ. LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease. J. Pharmacol. Exp. Ther. 2003; 306: 752-762.
20. Clarke CE, Lowry M. Basal ganglia metabolite concentrations in idiopathic Parkinson's disease and multiple system atrophy measured by proton magnetic resonance spectroscopy. Eur. J. Neurol. 2000; 7: 661-665.
21. Kickler N, Krack P, Fraix V, Lebas JF, Lamalle L, Durif F, Krainik A, Remy C, Segebarth C, Pollak P. Glutamate measurement in Parkinson's disease using MRS at 3 T field strength. NMR Biomed. 2007. DOI: 10.1002/NBM.1141.
22. 1H NMR spectra with increased magnetic field strength. J. Magn. Reson. 1998; 135: 260-264.
23. Di Costanzo A, Trojsi F, Tosetti M, Giannatempo GM, Nemore F, Piccirillo M, Bonavita S, Tedeschi G, Scarabino T. High-field proton MRS of human brain. Eur. J. Radiol. 2003; 48: 146-153.
24. Schubert F, Gallinat J, Seifert F, Rinneberg H. Glutamate concentrations in human brain using single voxel proton magnetic resonance spectroscopy at 3 Tesla. Neuroimage 2004; 21: 1762-1771.
25. Kantarci K, Reynolds G, Petersen RC, Boeve BF, Knopman DS, Edland SD, Smith GE, Ivnik RJ, Tangalos EG, Jack CR, Jr. Proton MR spectroscopy in mild cognitive impairment and Alzheimer disease: comparison of 1.5 and 3 T. AJNR Am J. Neuroradiol 2003; 24: 843-849.
26. Hattori N, Abe K, Sakoda S, Sawada T. Proton MR spectroscopic study at 3 Tesla on glutamate/glutamine in Alzheimer's disease. Neuroreport 2002; 13: 183-186.
27. Valenzuela MJ, Sachdev P. Magnetic resonance spectroscopy in AD. Neurology 2001; 56: 592-598.
28. 1H MR spectroscopy in common dementias. Neurology 2004; 63: 1393-1398.
29. Summerfield C, Gomez-Anson B, Tolosa E, Mercader JM, Marti MJ, Pastor P, Junque C. Dementia in Parkinson disease: a proton magnetic resonance spectroscopy study. Arch. Neurol. 2002; 59: 1415-1420.
30. Fahn S, Elton R, UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In Recent Developments in Parkinson's Disease, Fahn S, Marsden C, Calne D, Goldstein M (eds). Macmillan Healthcare Information: Florham Park, NJ, 1987; 153-163.
31. Griffith HR, den Hollander JA, Stewart CC, Evanochko WT, Buchthal SD, Harrell LE, Zamrini EY, Brockington JC, Marson DC. Elevated brain scyllo-inositol concentrations in patients with Alzheimer's disease. NMR Biomed. 2007; Published online 13 Feb 2007, DOI: 10.1002/nbm.1132.
32. 31P-NMR spectroscopy. NMR Biomed. 1996; 9: 217-227.
33. Cavassila S, Deval S, Huegen C, van Ormondt D, Graveron-Demilly D. Cramer-Rao bounds: an evaluation tool for quantitation. NMR Biomed. 2001; 14: 278-283.
34. SPSSInc. SPSS Base 10.0 Applications Guide. SPSS Inc: Chicago, 2000.
35. Cohen J. Statistical Power Analysis for the Behavioral Sciences, 2nd ed. Lawrence Erlbaum Associates, Inc.: Hillsdale, NJ, 1988.
36. 1H NMR spectra of human brain. Magn. Reson. Med. 1994; 32: 294-302.
37. Staner L. Surrogate outcomes in neurology, psychiatry, and psychopharmacology. Dialogues Clin. Neurosci. 2006; 8: 345-352.
38. Greenamyre JT. Pharmacological pallidotomy with glutamate antagonists. Ann. Neurol. 1996; 39: 557-558.
39. Meoni P, Bunnemann BH, Kingsbury AE, Trist DG, Bowery NG. NMDA NR1 subunit mRNA and glutamate NMDA-sensitive binding are differentially affected in the striatum and pre-frontal cortex of Parkinson's disease patients. Neuropharmacology 1999; 38: 625-633.
40. Gerlach M, Gsell W, Kornhuber J, Jellinger K, Krieger V, Pantucek F, Vock R, Riederer P. A post mortem study on neurochemical markers of dopaminergic, GABA-ergic and glutamatergic neurons in basal ganglia-thalamocortical circuits in Parkinson syndrome. Brain Res. 1996; 741: 142-152.
41. Kashani A, Betancur C, Giros B, Hirsch E, El Mestikawy S. Altered expression of vesicular glutamate transporters VGLUT1 and VGLUT2 in Parkinson disease. Neurobiol. Aging 2007; 28: 568-578.